Compare IDEXX Laboratories, Inc. (IDXX) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Oxford Lane Capital Corp — how do they compare? IDEXX Laboratories, Inc. trades at $518.89 (market cap $40.43B), while Oxford Lane Capital Corp trades at $8.57 (market cap $835.71M). The key difference: IDEXX Laboratories, Inc. is far larger — about 48.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Oxford Lane Capital Corp for 50 Days on average.
| IDXX | OXLC | |
|---|---|---|
Market Cap | $40.43B | $835.71M |
Volume | 692,164 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $766.68 | $16.74 |
52-Week Low | $504.70 | $8.15 |
Typical Hold Time | 46 Days | 50 Days |
Enterprise Value | $41.32B | $1.23B |
Dividend Yield | — | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
OXLC trades at $8.655, up 2.3% today, but remains in a bearish technical trend with significant earnings volatility. The company reported a net loss of $585 million in 2026, missing EPS estimates for three consecutive quarters, while maintaining a high dividend payout. Analyst sentiment is mixed with a 50% buy rating, but technical indicators show strong selling pressure.
The outlook is cautious due to deteriorating fundamentals and high payout risks, though the stock trades below book value. Key risks include unsustainable dividends and NAV erosion, while potential upside hinges on CLO market recovery and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
